| Indicator | Alone | Combined | ||
---|---|---|---|---|---|
RCT | Result | RCT | Result | ||
Benefit | Effective /% | 11 | 2.44;95%CI(1.87,3.19),P< 0.00001 | 20 | 3.7;95%CI(2.72,5.02),P< 0.00001 |
Morning stiffness /min | 13 | ‒3.83;95% CI (‒4.87, -2.8),P< 0.00001 | 20 | ‒10.51;95%CI (‒12.72,-8.31), P< 0.00001 | |
TJC | 13 | ‒0.95;95% CI (‒1.39, -0.51), P< 0.00001 | 17 | ‒0.82;95%CI (‒1.6,-0.03), P = 0.04 | |
SJC | 13 | ‒1.65;95% CI (‒2.1, -1.19), P< 0.00001 | 17 | ‒1.25;95% CI (‒1.98, -0.52), P = 0.0008 | |
ESR/mm/h | 11 | ‒5.15;95% CI (‒7.98, -2.23), P< 0.0004 | 26 | ‒6.96;95% CI (‒9.65, -4.27), P < 0.00001 | |
RF/IU/ml | 9 | ‒2.36;95% CI (‒3.25, -1.48), P < 0.00001 | 22 | ‒10.18;95% CI (‒16.4, -3.97), P = 0.001 | |
CRP/mg/L | 8 | ‒2.63;95% CI (‒5.49, -0.24), P = 0.07 | 19 | ‒5.14;95% CI (‒6.63, -3.66), P< 0.00001 | |
Risk | Adverse effects Rate /% | 6 | 0.39;95%CI (0.21,0.72), P = 0.003 | 20 | 0.62;95%CI (0.43,0.89), P = 0.008 |
Gastrointestinal reaction /% | 12 | 0.46;95%CI (0.19,1.12), P = 0.09 | 19 | 0.61;95%CI (0.43,0.85), P = 0.003 | |
Liver damage /% | 6 | 0.23;95%CI (0.07,0.73), P = 0.03 | 15 | 0.45;95%CI (0.26,0.78), P = 0.002 | |
Leucopenia /% | 8 | 0.51;95%CI (0.18,1.44), P = 0.2 | 17 | 0.48;95%CI (0.29,0.78), P = 0.003 | |
Skin lesions /% | 9 | 1.54;95%CI (0.61,3.89), P = 0.36 | 20 | 1.4;95%CI (0.88,2.23), P = 0.16 | |
Others/% | 7 | 0.13;95%CI (0.04,0.38), P = 0.0002 | 8 | 0.47;95%CI (0.25,0.88), P = 0.02 |